BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 5, 2026
$8.17
· % 处于52周区间
· 高于低点
· 至高点
$6.0052周低点
$11.2252周高点
市值 (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
收入 (TTM)
$941M
BCRX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$8.17
市值 (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
收入 (TTM)
$941M
ROE (TTM)
87.8%
负债/权益 (MRQ)
-0.9
52周区间
$6–$11
BCRX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 BioCryst Pharmaceuticals, Inc. - Common Stock 公司概况（来自维基百科）
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工435
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
自由现金流$345M2016-12-31 → 2025-12-31
净利率-40.9%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | BCRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | -5.55年均值 ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.25年均值 ≈6.7 | ≈6.7 | 29.2 | 低估 | |
| 市净率 (MRQ) | -4.65年均值 ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA (企业价值 / EBITDA) | 5.35年均值 ≈-281.5 | ≈-281.5 | · | · | |
| 股价/自由现金流 (TTM) | 5.65年均值 ≈-13.6 | ≈-13.6 | · | · | |
| 市现率 (TTM) | 5.55年均值 ≈-13.9 | ≈-13.9 | · | · | |
| 市值/营收 (TTM) | 2.35年均值 ≈6.3 | ≈6.3 | · | · | |
| 市值/自由现金流 (TTM) | 5.75年均值 ≈-14.4 | ≈-14.4 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | BCRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -33.3%5年均值 ≈-32.2% | ≈-32.2% | -1041.7% | 顶尖 | |
| EBITDA Margin (息税折旧摊销前利润率) | 39.1%5年均值 ≈-31.8% | ≈-31.8% | -1041.7% | 顶尖 | |
| 税前利润率 (TTM) | -40.5%5年均值 ≈-52.6% | ≈-52.6% | -493.4% | 顶尖 | |
| 净利润率 (TTM) | -40.9%5年均值 ≈-53.3% | ≈-53.3% | -990.1% | 顶尖 | |
| ROA (TTM) | -75.8%5年均值 ≈-18.2% | ≈-18.2% | -40.3% | 顶尖 | |
| ROE (TTM) | 87.8%5年均值 ≈42.1% | ≈42.1% | -55.6% | 弱 | |
| ROIC | -282.4%5年均值 ≈-118.5% | ≈-118.5% | -55.2% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | BCRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 负债/股东权益比率 (MRQ) | -0.95年均值 ≈-0.7 | ≈-0.7 | 0.0 | 低负债 | |
| 流动比率 (MRQ) | 2.35年均值 ≈3.7 | ≈3.7 | 6.7 | 低流动性 | |
| 速动比率 (MRQ) | 2.25年均值 ≈2.5 | ≈2.5 | 4.5 | 低流动性 | |
| 长期负债/股东权益 (MRQ) | -0.95年均值 ≈-0.7 | ≈-0.7 | 0.2 | 低负债 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | BCRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 94.1%5年均值 ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 47.8%5年均值 ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 117.9% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | BCRX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 1.75年均值 ≈0.8 | ≈0.8 | 0.1 | 顶尖 | |
| Inventory Turnover (库存周转率) | 2.85年均值 ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (应收账款周转率) | 9.45年均值 ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$2.0M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
23.2%
下次报告
十一月 02, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 3, 2026 | $0.30 | $0.12 | 148.1% |
| 2026年3月31日 | $-0.09 | $0.05 | -281.8% | |
| 2025年12月31日 | $0.01 | $0.04 | -74.1% | |
| 2025年9月30日 | $0.06 | $0.04 | 67.1% | |
| 2025年6月30日 | $0.04 | $0.01 | 179.7% | |
| 2025年3月31日 | $0.00 | $-0.07 | 100.0% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $875M | $451M | $331M | $271M | $157M |
| 营业利润率 % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| 净收入 | $264M | $-89M | $-227M | $-247M | $-184M |
| 稀释后每股收益 (EPS) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| 流动比率 | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| 速动比率 | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $345M | $-53M | $-97M | $-163M | $-145M |
机构持有人 (13F) 345 家申报者 · $2.8B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
345
持有价值
$2.8B
新仓位
55
已退出持仓
34
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 55 (-22 与上一季度对比) | 34 (-5 与上一季度对比) | 137 (+20 与上一季度对比) | 87 (+8 与上一季度对比) | +4.1M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $238930360 | 23893036 | 8.46% | 股份 |
| VANGUARD GROUP INC | $173732325 | 22273375 | 6.15% | 股份 |
| RA CAPITAL MANAGEMENT, L.P. | $158271860 | 15827186 | 5.61% | 股份 |
| STATE STREET CORP | $151910980 | 15191098 | 5.38% | 股份 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150964030 | 15096403 | 5.35% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $113642360 | 11364236 | 4.03% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111391580 | 11139158 | 3.95% | 股份 |
| TCG Crossover Management, LLC | $110209680 | 11020968 | 3.90% | 股份 |
| PERCEPTIVE ADVISORS LLC | $103088880 | 10308888 | 3.65% | 股份 |
| JANUS HENDERSON GROUP PLC | $84853520 | 8908506 | 3.01% | 股份 |
| Vestal Point Capital, LP | $83000000 | 8300000 | 2.94% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $67753490 | 6775349 | 2.40% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $62493232 | 6248046 | 2.21% | 股份 |
| Aberdeen Group plc | $53108710 | 5310871 | 1.88% | 股份 |
| UBS Group AG | $50782800 | 5078280 | 1.80% | 股份 |
| BANK OF AMERICA CORP /DE/ | $48012840 | 4801284 | 1.70% | 股份 |
| GOLDMAN SACHS GROUP INC | $44818738 | 4481874 | 1.59% | 股份 |
| Frazier Life Sciences Management, L.P. | $40092400 | 4009240 | 1.42% | 股份 |
| Nuveen, LLC | $40072370 | 4007237 | 1.42% | 股份 |
| MILLENNIUM MANAGEMENT LLC | $33947290 | 3394729 | 1.20% | 股份 |
| TWO SIGMA ADVISERS, LP | $31895074 | 4089112 | 1.13% | 股份 |
| RP Management, LLC | $28846155 | 3846154 | 1.02% | 股份 |
| JANE STREET GROUP, LLC | $27626830 | 2762683 | 0.98% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $27187810 | 2718781 | 0.96% | 股份 |
| Fisher Asset Management, LLC | $26040270 | 2604027 | 0.92% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $25302900 | 2530290 | 0.90% | 股份 |
| Kynam Capital Management, LP | $25226600 | 2522660 | 0.89% | 股份 |
| Candriam S.C.A. | $25125293 | 2514949 | 0.89% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23532910 | 2353291 | 0.83% | 股份 |
| RICE HALL JAMES & ASSOCIATES, LLC | $23320430 | 2332043 | 0.83% | 股份 |
| NORTHERN TRUST CORP | $22557310 | 2255731 | 0.80% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $22143020 | 2214302 | 0.78% | 股份 |
| MORGAN STANLEY | $19996852 | 1999684 | 0.71% | 股份 |
| Nantahala Capital Management, LLC | $19011600 | 1901160 | 0.67% | 股份 |
| Eversept Partners, LP | $18656530 | 1865653 | 0.66% | 股份 |
| ORBIMED ADVISORS LLC | $18520000 | 1852000 | 0.66% | 股份 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18449120 | 1844912 | 0.65% | 股份 |
| STIFEL FINANCIAL CORP | $18262340 | 1826234 | 0.65% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $17595730 | 1759573 | 0.62% | 股份 |
| CITADEL ADVISORS LLC | $17591600 | 1759160 | 0.62% | 股份 |
| JUPITER ASSET MANAGEMENT LTD | $16428740 | 1642874 | 0.58% | 股份 |
| IMC-Chicago, LLC | $16343360 | 1634336 | 0.58% | 股份 |
| Parkman Healthcare Partners LLC | $16242790 | 1624279 | 0.58% | 股份 |
| Legal & General Group Plc | $14555141 | 1455514 | 0.52% | 股份 |
| OP Asset Management Ltd | $13409900 | 1340990 | 0.48% | 股份 |
| Invesco Ltd. | $12337830 | 1233783 | 0.44% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11956510 | 1195651 | 0.42% | 股份 |
| Pictet Asset Management Holding SA | $11951392 | 1249771 | 0.42% | 股份 |
| BNP PARIBAS FINANCIAL MARKETS | $11740520 | 1174052 | 0.42% | 股份 |
| FIRST TRUST ADVISORS LP | $11204690 | 1120469 | 0.40% | 股份 |
激进投资者及 5%+ 股东 15 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 申报 | 2018年7月31日 | · | 初始申报 | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2018年4月2日 | · | 初始申报 | 被动投资 | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 申报 | 2016年8月16日 | · | 初始申报 | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 申报 | 2012年10月23日 | · | 初始申报 | 并购/出售 | SEC |
| Julian C. Baker, Felix J. Baker ×4 申报 | 2011年10月13日 | · | 初始申报 | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 申报 | 2007年8月20日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2005年12月7日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2005年12月7日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2005年12月7日 | · | 初始申报 | · | SEC |
| 未披露的报告人 | 2005年10月13日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2004年2月26日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2004年2月25日 | · | 初始申报 | · | SEC |
| 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2004年2月24日 | · | 初始申报 | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 申报 | 2003年10月31日 | · | 初始申报 | · | SEC |
| William W. Featheringill | 2002年2月14日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 51 位内幕人士 · 21 位高管 · 30 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 2025年12月17日 A | 268700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 2024年12月19日 A | 377867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 2020年2月21日 A | 125176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 2011年3月16日 M | 57102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 2025年12月22日 M | 952583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 2008年3月14日 A | 65730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 2026年5月13日 M | 400703 | 0 | 7 | $-3461969 |
| Sandeep Menon | Chief R&D Officer | 2026年4月6日 A | 205150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 2025年3月31日 F | 377318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 2022年12月19日 A | 16653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 2022年11月14日 M | 298541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 2022年3月10日 M | 37954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 2020年12月15日 A | 45000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 2019年1月28日 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 2012年3月15日 F | 24124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 2011年2月7日 A | 9766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 2010年3月12日 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 2008年7月31日 P | 3048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 2007年7月31日 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 2007年7月31日 P | 3659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 2007年5月16日 A | 1928 | 0 | 0 | $0 |
| Amy E Mckee | 董事 | 2026年8月31日 A | 47821 | 0 | 1 | $-100285 |
| Jill C. Milne | 董事 | 2026年8月31日 A | 33226 | 0 | 0 | $0 |
| Steven Frank | 董事 | 2026年8月31日 A | 36747 | 0 | 0 | $0 |
| Jon P Stonehouse | 董事 | 2026年8月31日 A | 1340419 | 0 | 0 | $0 |
| Vincent Milano | 董事 | 2026年8月31日 A | 109642 | 0 | 0 | $0 |
| Theresa Heggie | 董事 | 2026年6月11日 A | 80646 | 0 | 1 | $-504823 |
| Machelle Sanders | 董事 | 2026年6月11日 A | 45936 | 0 | 1 | $-68544 |
| Steven K Galson | 董事 | 2026年6月11日 A | 27794 | 0 | 0 | $0 |
| Alan G Levin | 董事 | 2026年6月11日 A | 79565 | 0 | 0 | $0 |
| Nancy J Hutson | 董事 | 2025年6月12日 A | 99138 | 0 | 0 | $0 |
| George B Abercrombie | 董事 | 2024年6月12日 A | 36431 | 0 | 0 | $0 |
| Steve Aselage | 董事 | 2024年6月12日 A | 70159 | 0 | 0 | $0 |
| Kenneth B Lee JR | 董事 | 2023年6月13日 A | 68863 | 0 | 0 | $0 |
| Robert Alexander Ingram | 董事 | 2023年2月28日 A | 100198 | 0 | 0 | $0 |
| Stanley C Erck | 董事 | 2018年11月28日 M | 48333 | 0 | 0 | $0 |
| Fred Cohen | 董事 | 2018年6月20日 A | 119410 | 0 | 0 | $0 |
| Sanj K Patel | 董事 | 2017年5月24日 A | · | 0 | 0 | $0 |
| Charles A Sanders | 董事 | 2016年2月29日 A | 12971 | 0 | 0 | $0 |
| Peder Jensen | 董事 | 2014年5月2日 A | 60000 | 0 | 0 | $0 |
| John L Higgins | 董事 | 2012年5月23日 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | 董事 | 2012年5月23日 A | 3000 | 0 | 0 | $0 |
| Stephen R Biggar | 董事 | 2011年5月12日 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | 董事 | 2010年5月13日 A | 3000 | 0 | 0 | $0 |
| William W Featheringill | 董事 | 2010年5月13日 A | 231538 | 0 | 0 | $0 |
| William M Spencer III | 董事 | 2007年5月16日 A | 186761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | 董事 | 2007年5月16日 A | 451900 | 0 | 0 | $0 |
| Charles E Bugg | 董事 | 2007年3月18日 A | 62439 | 0 | 0 | $0 |
| GORDON CARL L | 董事 | 2006年5月17日 A | 1100000 | 0 | 0 | $0 |
| John A Montgomery | 董事 | 2003年11月4日 M | 46785 | 0 | 0 | $0 |
| Randolph C Steer | · | 2008年5月21日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 41 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2.34% | 1193733 SH | 2026年10月2日 | 每日 |
| BBP · ETFis Series Trust I | 1.42% | 155993 NS | 2026年7月31日 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0.99% | 510 NS | 2026年7月31日 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0.92% | 1078429 NS | 2026年7月31日 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.62% | 248560 NS | 2026年7月31日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.59% | 324702 NS | 2026年7月31日 | N-PORT |
| FYC · First Trust Exchange-Traded Alpha... | 0.36% | 516595 NS | 2026年7月31日 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Inde... | 0.22% | 73039 SH | 2026年10月2日 | 每日 |
| PWS · Pacer Funds Trust | 0.17% | 4436 NS | 2026年7月31日 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.14% | 249665 SH | 2026年8月19日 | 每日 |
| ESSC · Strategy Shares | 0.14% | 5593 NS | 2026年7月31日 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.14% | 18119 SH | 2026年10月2日 | 每日 |
| IBB · iShares Trust | 0.13% | 1651139 SH | 2026年9月11日 | 每日 |
| IWO · iShares Trust | 0.13% | 2178966 SH | 2026年9月11日 | 每日 |
| FYX · First Trust Exchange-Traded Alpha... | 0.11% | 174467 NS | 2026年7月31日 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund ... | 0.08% | 64429 NS | 2026年7月31日 | N-PORT |
| FAD · First Trust Exchange-Traded Alpha... | 0.07% | 46799 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 1339774 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.07% | 111471 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.06% | 75067 SH | 2026年9月11日 | 每日 |
| IWM · iShares Trust | 0.06% | 5937121 SH | 2026年9月11日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.06% | 202979 SH | 2026年10月2日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.05% | 770732 NS | 2026年7月31日 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.04% | 1696014 SH | 2026年8月19日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2837341 SH | 2026年8月19日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.03% | 624412 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 99007 NS | 2026年7月31日 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.02% | 2922024 SH | 2026年8月19日 | 每日 |
| WSML · iShares Trust | 0.01% | 11812 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.00% | 72998 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.00% | 336323 SH | 2026年9月11日 | 每日 |
| DFUS · Dimensional ETF Trust | 0.00% | 52194 NS | 2026年7月31日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 36571 NS | 2026年7月31日 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 632 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 286 NS | 2026年7月31日 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 8070274 SH | 2026年8月19日 | 每日 |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.00% | 196622 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 19676 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.00% | 51624 SH | 2026年8月19日 | 每日 |
| ISCB · iShares Trust | · | 10494 SH | 2026年9月11日 | 每日 |
| SMLF · iShares Trust | · | 766086 SH | 2026年9月11日 | 每日 |
BCRX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 17 位分析师
买入
中位数目标
$17.00
+108.1%
5 29.4%
强烈买入
10 58.8%
买入
2 11.8%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
11 位分析师 · 2026-09-28平均目标 $20.64 +152.6%
← 低于所有目标
当前价格 $8.17
最低$11.00
平均值$20.64
最高$32.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
最新新闻 提及该公司的近期头条新闻
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 5, 2026 申报